Print Share

Policies and Guidelines

Guidelines

Joint Commission’s Sentinel Event Alert on Suicide (November 2010)
FDA Medication Guides
ASHP’s REMS Resource Center – Contains information on the FDA’s post-marketing surveillance processes that are designed to ensure safety of all medications

FDA Reports

FDA updates information on Suicidal Behavior and Ideation and Antiepileptic Drugs - May 5, 2009
FDA issues Public Health Advisory to alert physicians of reports of suicidal thinking in children and adolescents associated with Strattera (atomoxetine) - September 29, 2005
FDA notifies healthcare professionals about the increased risks of suicidal thinking and behavior in young adults ages 18 to 24 years old during the first one to two months of antidepressant treatment - May 2, 2007
FDA issues Public Health Advisory about new boxed warnings for the Smoking Cessation Drugs Chantix and Zyban - July 1, 2009
FDA provides healthcare professionals with updated information neuropsychiatric adverse events associated with leukotriene inhibitors (montelukast, zafirlukast and zileuton) - August 28, 2009
FDA notifies healthcare professionals of strengthened warnings for tramadol to emphasizes the risk of suicide for patients who are addiction-prone, taking tranquilizers or antidepressant drugs and also warns of the risk of overdosage - May 25, 2010

©2012 American Society of Health-System Pharmacists. All rights reserved. 7272 Wisconsin Avenue, Bethesda, MD 20814
Copyright | Trademark | Privacy Policy